ALYREF (Aly/REF export factor): A potential biomarker for predicting cancer occurrence and therapeutic efficacy

Area of Science:

• Biochemistry
• Epigenetics
• Molecular Biology

Background:

• 5-Methylcytosine (m5C) is a crucial RNA epigenetic modification.
• ALYREF, an RNA-binding protein, is implicated in malignant phenotypes and treatment resistance.
• Current clinical applications and drug trials targeting ALYREF are limited.

Purpose of the Study:

• To review the literature on ALYREF's role in carcinogenesis.
• To highlight ALYREF's significance as a prognostic biomarker.
• To emphasize ALYREF as a potential therapeutic target.

Main Methods:

• Literature review of ALYREF's functions.
• Analysis of ALYREF's involvement in cancer progression.
• Examination of ALYREF's regulatory mechanisms.

Main Results:

• Aberrant ALYREF expression drives proliferation, metastasis, and drug resistance.
• ALYREF influences pre-mRNA processing, mRNA stability, and nuclear-cytoplasmic shuttling.
• Evidence suggests ALYREF's role in cancer prognosis.

Conclusions:

• ALYREF is a key regulator of malignant phenotypes.
• ALYREF holds promise as an early prevention biomarker.
• Targeting ALYREF presents a potential therapeutic strategy for cancer.